EBV in MS: guilty by association?

Trends in Immunology

Volumn 30, Issue 6, 2009, Pages 243-248

  Lünemann, Jan D ^a   Münz, Christian ^a  

^a INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BYSTANDER EFFECT; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HUMAN; IMMUNE RESPONSE; MONONUCLEOSIS; MULTIPLE SCLEROSIS; T LYMPHOCYTE ACTIVATION; VIRUS CELL INTERACTION; VIRUS INFECTION;

ADULT; ANTIGEN PRESENTATION; AUTOANTIGENS; AUTOIMMUNITY; B-LYMPHOCYTES; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; HERPESVIRUS 4, HUMAN; HUMANS; INFECTIOUS MONONUCLEOSIS; INFLAMMATION; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 66549109540     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2009.03.007     Document Type: Article

References (80)

1. Hafler D.A., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357 (2007) 851-862
2. Lundmark F., et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39 (2007) 1108-1113
3. Gregory S.G., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 39 (2007) 1083-1091
4. Dyment D.A., et al. Genetics of multiple sclerosis. Lancet Neurol. 3 (2004) 104-110
5. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
6. Dean G., et al. Multiple sclerosis among immigrants in Greater London. BMJ 1 (1976) 861-864
7. Ebers G.C., et al., Canadian Collaborative Study Group. A genetic basis for familial aggregation in multiple sclerosis. Nature 377 (1995) 150-151
8. Sadovnick A.D., et al., The Canadian Collaborative Study Group. Evidence for genetic basis of multiple sclerosis. Lancet 347 (1996) 1728-1730
9. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1 (2001) 75-82
10. Hislop A.D., et al. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25 (2007) 587-617
11. Warner H.B., and Carp R.I. Multiple sclerosis and Epstein-Barr virus. Lancet 2 (1981) 1290
12. Thacker E.L., et al. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59 (2006) 499-503
13. Nielsen T.R., et al. Multiple sclerosis after infectious mononucleosis. Arch. Neurol. 64 (2007) 72-75
14. Ramagopalan S.V., et al., A Population-Based Study. Association of Infectious Mononucleosis with Multiple Sclerosis. Neuroepidemiology 32 (2009) 257-262
15. Ascherio A., and Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 11 (2000) 220-224
16. Alotaibi S., et al. Epstein-Barr virus in pediatric multiple sclerosis. J. Am. Med. Assoc. 291 (2004) 1875-1879
17. Pohl D., et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 67 (2006) 2063-2065
18. Banwell B., et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 6 (2007) 773-781
19. Lünemann J.D., et al. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 71 (2008) 1033-1035
20. Sundstrom P., et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62 (2004) 2277-2282
21. Levin L.I., et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. J. Am. Med. Assoc. 293 (2005) 2496-2500
22. DeLorenze G.N., et al. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 63 (2006) 839-844
23. Lünemann J.D., et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129 (2006) 1493-1506
24. Lünemann J.D., et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J. Exp. Med. 205 (2008) 1763-1773
25. Serafini B., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204 (2007) 2899-2912
26. Salmi A.A., et al. Measles virus antibody in cerebrospinal fluids from patients with multiple sclerosis. BMJ 1 (1972) 477-479
27. Vartdal F., et al. Viral and bacterial antibody responses in multiple sclerosis. Ann. Neurol. 8 (1980) 248-255
28. Derfuss T., et al. Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J. Neurol. 252 (2005) 968-971
29. Jacobi C., et al. Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: discrimination between microorganism-driven and polyspecific immune response. J. Neuroimmunol. 187 (2007) 139-146
30. Jarius S., et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 79 (2008) 1134-1136
31. Hansen B.S., et al. Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J. Neuroimmunol. 172 (2006) 94-103
32. Wolf N.A., et al. Synergistic interaction between Toll-like receptor agonists is required for induction of experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 185 (2007) 115-122
33. Prinz M., et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 116 (2006) 456-464
34. Lim W.H., et al. Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood 109 (2007) 1043-1050
35. Lovett-Racke A.E., et al. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest. 101 (1998) 725-730
36. - costimulation-independent T cells in multiple sclerosis. J. Clin. Invest. 108 (2001) 1185-1194
37. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199 (2004) 971-979
38. van Zwam M., et al. Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J. Mol. Med. 87 (2009) 273-286
39. Sutkowski N., et al. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 15 (2001) 579-589
40. Tai A.K., et al. Human endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis. Mult. Scler. 14 (2008) 1175-1180
41. Wekerle H., et al. Animal models. Ann. Neurol. 36 Suppl (1994) S47-S53
42. Langrish C.L., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201 (2005) 233-240
43. Frohman E.M., et al. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354 (2006) 942-955
44. Stuve O., et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59 (2006) 743-747
45. Qin Y., et al. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 102 (1998) 1045-1050
46. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192 (2000) 393-404
47. Colombo M., et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 164 (2000) 2782-2789
48. + T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2428-2433
49. Scholz C., et al. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J. Immunol. 160 (1998) 1532-1538
50. + T cells in multiple sclerosis. J. Immunol. 172 (2004) 3893-3904
51. Bielekova B., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6 (2000) 1167-1175
52. Muraro P.A., et al. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain 126 (2003) 20-31
53. Meinl E., et al. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J. Clin. Invest. 92 (1993) 2633-2643
54. Goebels N., et al. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 123 (2000) 508-518
55. Harari A., et al. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 16233-16238
56. Lindsey J.W., et al. Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis. Mult. Scler. 15 (2009) 153-158
57. + T-cell response in patients with early multiple sclerosis. Brain 131 (2008) 1712-1721
58. Pender M.P., et al. Decreased T-cell reactivity to Epstein-Barr virus-infected lymphoblastoid cell lines in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 80 (2008) 498-505
59. Hauser S.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358 (2008) 676-688
60. Bar-Or A., et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 63 (2008) 395-400
61. McFarland H.F. The B cell-old player, new position on the team. N. Engl. J. Med. 358 (2008) 664-665
62. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 314 (1985) 537-539
63. Aloisi F., and Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6 (2006) 205-217
64. Magliozzi R., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130 (2007) 1089-1104
65. Franciotta D., et al. B cells and multiple sclerosis. Lancet Neurol. 7 (2008) 852-858
66. Caldwell R.G., et al. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9 (1998) 405-411
67. Chen C., et al. Editing disease-associated autoantibodies. Immunity 6 (1997) 97-105
68. Samuels J., et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 201 (2005) 1659-1667
69. Yurasov S., et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201 (2005) 703-711
70. Tiller T., et al. Autoreactivity in human IgG+ memory B cells. Immunity 26 (2007) 205-213
71. Pender M.P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 24 (2003) 584-588
72. Traggiai E., et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304 (2004) 104-107
73. Melkus M.W., et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12 (2006) 1316-1322
74. Fingeroth J.D., et al. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 4510-4514
75. Li Q., et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J. Virol. 71 (1997) 4657-4662
76. + T lymphocytes. Nature 421 (2003) 852-856
77. + T cells. Nat. Immunol. 7 (2006) 475-481
78. + T cells during the primary immune response to Epstein-Barr virus In vivo. J. Exp. Med. 187 (1998) 1395-1402
79. + T cell memory in vivo. Eur. J. Immunol. 28 (1998) 4382-4390
80. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162 (1999) 1827-1835